antiprimod
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2004 (NCT00086216)
Timeline
Indications
Mechanism of action
- Vascular endothelial growth factor AINHIBITOR
VEGFA inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- antiprimod
- atiprimod
- atiprimod
- atiprimod
- azaspirane
- n,n-diethyl-8,8-dipropyl-2-azaspiro(4.5)decane-2-propanamine dihydrochloride
- sk&f 106615
- sk&f-106615
- skf 106615
- skf-106615
- sk&f 106615, dihydrochloride
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00663429 | Phase 2 | Nov 1, 2007 | Callisto Pharmaceuticals |
| NCT00388063 | Phase 2 | Oct 1, 2006 | Callisto Pharmaceuticals |
| NCT00214838 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2005 | Callisto Pharmaceuticals |
| NCT00430014 | Phase 1 | Mar 1, 2005 | Callisto Pharmaceuticals, University of Texas at Houston |
| NCT00086216 | Phase 1/Phase 2 (Phase 2) | May 1, 2004 | Callisto Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Callisto Pharmaceuticals | For profit | 5 | 4 | 2 | 2004 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2005 |
2 organizations
Page 1 / 1